10-Q: Allurion Technologies Reports Q3 2024 Results: Revenue Declines Amidst Restructuring

Allurion Technologies experienced a significant revenue decrease in Q3 2024, alongside a restructuring plan aimed at reducing operating costs.

Summary

• Allurion Technologies reported a revenue of $5.4 million for the third quarter of 2024, a decrease of 71% compared to the same period in 2023.
• The company's revenue for the first nine months of 2024 was $26.5 million, a 41% decrease compared to the same period in 2023.
• The decrease in revenue was primarily due to lower sales of gastric balloons and the suspension of sales in France.
• The company's gross profit for the third quarter of 2024 was $3.1 million, a 78% decrease compared to the same period in 2023.
• Operating expenses decreased by 63% to $15.5 million in Q3 2024, driven by reductions in sales, marketing, and R&D costs.
• Allurion reported a net loss of $9.0 million for the third quarter of 2024 and a net loss of $5.6 million for the first nine months of 2024.
• The company's cash and cash equivalents were $28.7 million as of September 30, 2024.
• A restructuring plan was approved on November 6, 2024, which includes a 50% workforce reduction and is expected to incur $3.5 million in restructuring charges.

Sentiment

Score: 3

Explanation: The document presents a concerning financial picture with significant revenue declines, net losses, and non-compliance with NYSE listing standards. While cost-cutting measures are being implemented, the overall sentiment is negative due to the challenges the company faces.

Positives

• Operating expenses decreased significantly in Q3 2024, driven by reductions in sales, marketing, and R&D costs.
• The company has taken steps to address material weaknesses in internal control over financial reporting.
• The company has implemented a remediation plan to address concerns raised by the French regulatory authority (ANSM).

Negatives

• Revenue decreased significantly in Q3 2024 and for the first nine months of 2024.
• Gross profit decreased significantly in Q3 2024 and for the first nine months of 2024.
• The company reported a net loss for both Q3 2024 and the first nine months of 2024.
• The company is not in compliance with the NYSE's minimum share price requirement or its minimum market capitalization standard and is at risk of being delisted.
• The company has suspended sales of the Allurion Balloon in France.

Risks

• The company's ability to achieve and maintain profitability depends on the commercial success of the Allurion Balloon.
• The company's ability to obtain regulatory approvals or clearances in the United States and other international jurisdictions is uncertain.
• The company's products may be removed from the market due to a variety of factors, including adverse events, recalls, or suspension of regulatory clearance to sell.
• The company is not in compliance with the NYSE's minimum share price requirement or its minimum market capitalization standard and is at risk of being delisted.
• The company has a significant amount of debt, which may affect its ability to operate its business and secure additional financing in the future.

Future Outlook

The company expects to continue to incur net losses for the foreseeable future as it focuses on obtaining regulatory approvals, reinstating regulatory approvals, refining sales and marketing strategies, and continuing research and development efforts. The company also expects to incur additional costs associated with operating as a public company.

Management Comments

• The company has implemented a remediation plan to address concerns raised by the French regulatory authority (ANSM).
• The company intends to monitor the closing bid price of its Common Stock and may consider available options to regain compliance with the NYSE minimum share price requirement.
• The company has submitted a plan to the NYSE outlining measures designed to regain compliance with the continued listing standard within 18 months of receipt the written notice.

Industry Context

The medical device industry is highly competitive and rapidly changing. Allurion faces competition from other companies offering weight loss solutions, including pharmaceutical therapies and bariatric surgical treatments. The company's performance is also affected by macroeconomic conditions and regulatory changes.

Comparison to Industry Standards

• The company's revenue decline is significant compared to the growth rates of some other medical device companies in the weight loss sector.
• The company's net loss is also significant, indicating challenges in achieving profitability.
• The company's cash position is relatively low compared to some of its competitors, which may limit its ability to invest in growth initiatives.
• The company's non-compliance with NYSE listing standards is a concern, as it could lead to delisting and negatively impact investor confidence.
• The company's suspension of sales in France is a setback, as France is a key market for medical devices.

Related Party Transactions

• The company has disclosed several related-party transactions, including a lease agreement, consulting agreements, a convertible note, and participation in the Public Offering and Private Placement.

Stakeholder Impact

• Shareholders are negatively impacted by the decrease in revenue, net losses, and the risk of delisting from the NYSE.
• Employees are negatively impacted by the restructuring plan, which includes a 50% workforce reduction.
• Customers may be impacted by the suspension of sales in France and any potential delays in product availability.
• Suppliers may be impacted by the company's restructuring plan and any potential changes in purchasing patterns.
• Creditors may be impacted by the company's financial performance and its ability to service its debt obligations.

Next Steps

• The company will focus on implementing its restructuring plan to reduce operating costs.
• The company will work to regain compliance with the NYSE's minimum share price requirement and minimum market capitalization standard.
• The company will continue to engage with ANSM to identify a path that will enable the company to resume the commercialization of the Allurion Balloon in France.
• The company will continue to pursue regulatory approvals for its products in new markets.
• The company will continue to refine its sales and marketing strategies.

Key Dates

Keywords

Allurion Balloon, weight loss, gastric balloon, revenue, net loss, restructuring, NYSE, regulatory approval, clinical trials, medical device